CO6280527A2 - Derivados de amina aromáticos de ácido pentanoico como moduladores de gama secretasa - Google Patents

Derivados de amina aromáticos de ácido pentanoico como moduladores de gama secretasa

Info

Publication number
CO6280527A2
CO6280527A2 CO10048726A CO10048726A CO6280527A2 CO 6280527 A2 CO6280527 A2 CO 6280527A2 CO 10048726 A CO10048726 A CO 10048726A CO 10048726 A CO10048726 A CO 10048726A CO 6280527 A2 CO6280527 A2 CO 6280527A2
Authority
CO
Colombia
Prior art keywords
secretase
amine
pentanoic acid
aromatic derivatives
range modulators
Prior art date
Application number
CO10048726A
Other languages
English (en)
Inventor
Chih Yung Ho
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO6280527A2 publication Critical patent/CO6280527A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/88—Unsaturated compounds containing keto groups containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con los compuestos de la Fórmula (I) como se describe en la presente, en donde las definiciones de A, X, R1, R2, R3, R4, R5, R6, R7 y R8 se proporcionan en la descripción. Los compuestos de la Fórmula (I) son útiles para el tratamiento de enfermedades asociadas con la actividad ?-secretasa, que incluye la enfermedad de Alzheimer.
CO10048726A 2007-10-19 2010-04-26 Derivados de amina aromáticos de ácido pentanoico como moduladores de gama secretasa CO6280527A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98120907P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
CO6280527A2 true CO6280527A2 (es) 2011-05-20

Family

ID=40338749

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10048726A CO6280527A2 (es) 2007-10-19 2010-04-26 Derivados de amina aromáticos de ácido pentanoico como moduladores de gama secretasa

Country Status (17)

Country Link
US (1) US8692017B2 (es)
EP (1) EP2215043B1 (es)
JP (1) JP5417334B2 (es)
KR (1) KR101618068B1 (es)
CN (1) CN101896452B (es)
AU (1) AU2008312355B2 (es)
BR (1) BRPI0818773A2 (es)
CA (1) CA2702959C (es)
CO (1) CO6280527A2 (es)
CR (1) CR11448A (es)
EA (1) EA019710B1 (es)
ES (1) ES2401833T3 (es)
IL (1) IL205046A (es)
MX (1) MX2010004310A (es)
NI (1) NI201000065A (es)
WO (1) WO2009052334A1 (es)
ZA (1) ZA201003520B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1799672B1 (en) * 2004-10-07 2013-01-02 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
AU2008312612B2 (en) 2007-10-19 2013-11-28 Janssen Pharmaceutica, N.V. Piperidinyl and piperazinyl modulators of gamma-secretase
AU2008312355B2 (en) 2007-10-19 2013-07-04 Janssen Pharmaceutica, N.V. Carbon linked modulators of y-secretase
WO2009052350A1 (en) 2007-10-19 2009-04-23 Janssen Pharmaceutica, N.V. Amine linked modulators of y-secretase
CN105801350B (zh) * 2016-04-29 2018-07-27 宜春学院 二芳基甲醇类化合物的合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790287A (fr) * 1971-10-28 1973-04-19 Delalande Sa Acides pyrimidin-6yl acethydroxamiques, leur procede de preparation et leur application en therapeutique
BE826017R (fr) * 1974-03-19 1975-08-26 Acides pyrimidin-6yl acethydroxamiques, leur procede de preparation et leur application en therapeutique
US4252951A (en) * 1979-10-09 1981-02-24 Eli Lilly And Company Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
US5391817A (en) * 1993-12-21 1995-02-21 Bristol-Myers Squibb Biaryl phospholipase A2 inhibitors
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
DE10131899A1 (de) 2001-07-04 2003-02-27 Boehringer Ingelheim Pharma In vitro-Screening-Assay für gamma-Secretase
CN1829521B (zh) * 2003-06-16 2011-01-26 安纳考尔医药公司 耐水解的含硼治疗剂和使用方法
WO2006004555A1 (en) 2004-06-30 2006-01-12 Paysetter Pte Ltd System and method for facilitating transfer of physical money and/or credit
DE102004033876B4 (de) 2004-07-13 2009-01-15 Christoph Kaesbohrer Dreidimensionales Struktursystem
GB0416508D0 (en) * 2004-07-23 2004-08-25 Merck Sharp & Dohme Therapeutic agents
EP1650183A1 (en) 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
SI1849762T1 (sl) 2006-04-21 2009-12-31 Cellzome Ltd Substituirane bifenil karboksilne kisline in derivati le-teh
ATE445586T1 (de) 2006-04-21 2009-10-15 Cellzome Ltd Terphenylderivate zur alzheimerbehandlung
CA2654784A1 (en) * 2006-06-09 2007-12-13 Icos Corporation Substituted phenylacetic acids as dp-2 antagonists
EA200802417A1 (ru) 2006-06-09 2009-06-30 Икос Корпорейшн Замещенные фенилуксусные кислоты как dp-2-антагонисты
AU2008312771B2 (en) * 2007-10-17 2012-11-01 Janssen Pharmaceutica, N.V. Biphenyl carboxylic acids and derivatives thereof
AU2008312612B2 (en) * 2007-10-19 2013-11-28 Janssen Pharmaceutica, N.V. Piperidinyl and piperazinyl modulators of gamma-secretase
US7951843B2 (en) * 2007-10-19 2011-05-31 Janssen Pharmaceutica N.V. Amide linked modulators of γ-secretase
AU2008312355B2 (en) 2007-10-19 2013-07-04 Janssen Pharmaceutica, N.V. Carbon linked modulators of y-secretase
AU2008312362A1 (en) * 2007-10-19 2009-04-23 Janssen Pharmaceutica, N.V. Gsm intermediates
WO2009052350A1 (en) * 2007-10-19 2009-04-23 Janssen Pharmaceutica, N.V. Amine linked modulators of y-secretase
US7968725B2 (en) 2008-07-22 2011-06-28 Janssen Pharmaceutica N.V. Pyridinyl modulators of γ-secretase

Also Published As

Publication number Publication date
EA201070496A1 (ru) 2010-10-29
CA2702959C (en) 2016-07-26
CN101896452B (zh) 2013-07-31
JP5417334B2 (ja) 2014-02-12
ES2401833T3 (es) 2013-04-24
CA2702959A1 (en) 2009-04-23
US8692017B2 (en) 2014-04-08
NI201000065A (es) 2010-09-13
MX2010004310A (es) 2010-05-03
EA019710B1 (ru) 2014-05-30
IL205046A0 (en) 2010-11-30
EP2215043A1 (en) 2010-08-11
AU2008312355A1 (en) 2009-04-23
US20090105288A1 (en) 2009-04-23
KR20100090688A (ko) 2010-08-16
AU2008312355B2 (en) 2013-07-04
BRPI0818773A2 (pt) 2015-04-14
WO2009052334A1 (en) 2009-04-23
ZA201003520B (en) 2012-07-25
CN101896452A (zh) 2010-11-24
EP2215043B1 (en) 2013-03-06
KR101618068B1 (ko) 2016-05-04
CR11448A (es) 2011-01-14
JP2011500719A (ja) 2011-01-06
IL205046A (en) 2014-09-30

Similar Documents

Publication Publication Date Title
ECSP12011622A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
HN2012001413A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos
UY29963A1 (es) Compuestos terapéuticos: piridinas y pirazinas como andamios
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
ECSP066879A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
UY31093A1 (es) Compuestos de ariloazol-2-il cianoetilamino, método para prepararlos y método para utilizarlos
CR10948A (es) Compuestos triciclicos, composiciones y procedimientos
CO6361989A2 (es) Proceso para la preparacion de derivados de l-alanina protegidos
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
CO6341617A2 (es) 5-alquinil-pirimidinas
PA8855001A1 (es) Monocarbamas
ECSP11010816A (es) Nuevos Compuestos
CO6280527A2 (es) Derivados de amina aromáticos de ácido pentanoico como moduladores de gama secretasa
UY33176A (es) Derivados de oxazolopirimidina sustituida en 2, 5, 7.
CO6280529A2 (es) DERIVADOS DE AMIDA AROMÁTICOS DE ÁCIDO PENTANOICO COMO MODULADORES DE γ - SECRETOSA
CR9472A (es) Derivados de aminoacidos
ECSP10010532A (es) Tiazolil-dihidro-indazoles
UY32747A (es) 2-carboxamida-cicloamino-ureas sustituidas
UY33177A (es) Derivados de ácido carboxílico que comprenden un anillo de oxazolopirimidina 2, 5, 7-sustituido
UY33180A (es) Derivados de ácido carboxílico heterocíclicos que comprenden un anillo de oxazolopirimidina 2,5-sustituida.
UY33179A (es) Derivados de ácido carboxílico que comprenden un anillo de oxazolopirimidina 2,5-sustituido.
ECSP088280A (es) Compuestos de imidazol para el tratamiento de trastornos neurológicos
BRPI0817433A2 (pt) Moduladores de gama-secretase piperidinila e piperazinila
UY32002A (es) Piridinilo moduladores de gamma-secretasa

Legal Events

Date Code Title Description
FC Application refused